Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The intensity of angiogenesis, as measured by microvessel density, is a strong independent predictor of survival in breast carcinoma patients. The impact of chemotherapy and/or endocrine therapy on this process is unknown. METHODS: Histologic samples from patients randomized to a trial of neoadjuvant (NEO) versus adjuvant (ADJ) chemoendocrine therapy for operable breast carcinoma were obtained. Samples from 195 patients (90 NEO samples and 105 ADJ samples) were analyzed. Immunostaining was performed with the CD34 monoclonal antibody and the scoring of microvessels was performed using the Chalkley method. RESULTS: The median score of the NEO patients was 5.7 (95% confidence interval [CI], 5.3-6.0) and the median score of the ADJ patients was 6.3 (95% CI, 6-6.7) (P=0.025). Using previously validated scoring categories, there were fewer samples with a poor prognosis (score > or =7) in the NEO group (26%) compared with the ADJ group (32%) (P=0.04). CONCLUSIONS: The results of the current study suggest that NEO chemoendocrine therapy causes a reduction in microvessel density in primary breast carcinomas, which could be secondary to tumor regression or due to a direct effect on angiogenesis.

Original publication

DOI

10.1002/(sici)1097-0142(19990501)85:9<1996::aid-cncr17>3.0.co;2-h

Type

Journal article

Journal

Cancer

Publication Date

01/05/1999

Volume

85

Pages

1996 - 2000

Keywords

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Immunohistochemistry, Mastectomy, Middle Aged, Neoadjuvant Therapy, Neovascularization, Pathologic, Prognosis, Tamoxifen